Startup Stage: Proof of Concept/Prototype

Support Required: Funding

Fund requirement (): 8000000

Structure of the Company: PVT Ltd.

Website: https://heamac.com/

---

Business Overview

---

Executive Summary: Heamac is an offshoot of IIT Hyderabad. We are a team of Product Designers, Biomedical engineers, doctors, Biodesign fellows who want to create impact through Design innovation in Healthtech. Ours is a design-driven MedTech startup with empathy towards neonatal care. Our vision is to provide solutions with Zero Separation between child and mother. We are currently working on our first product nLite 360TM, an intelligent phototherapy device that does uninterrupted treatment and timely monitoring of the jaundiced neonate thereby ensuring complete care.

Market need: We are addressing the need for critical jaundice cases. Jaundice is Just after birth, an inevitable condition. Every 6 out of 10 newborns are affected by jaundice. And in developing countries, 45% of these cases are severe conditions leading to mortality or lifetime disabilities. In INDIA alone 6.7 Million babies are suffering from severe Jaundice which may lead to Death or lifetime Disabilities. About 42 million babies are born with severe jaundice across the world who need intense Phototherapy. There is no dedicated device to treat severe jaundice. In corporate hospitals, they treat these cases by following indigenous methods by pooling in multiple devices. But in rural and low-resource settings there is no scope of treating these babies and even if there is a possibility, it is less than 5%. Hence these babies are left untreated. Heamac sees the huge potential in the area as the market size for neonatal Phototherapy devices is USD 1.2 billion for India alone. The Asia- Pacific and Indian baby market is growing at 5 per cent CAGR due to the rise in the number of maternal and child care hospitals and the demand for robust technologies at-home care.

Product/Service description: Our product is one of its kind in the healthcare sector. It is the first-ever device that caters to severe neonatal jaundice. Our device is a standalone phototherapy device that caters to all jaundice cases and particularly severe jaundice cases. The device is carefully curated to user-centric design which enables even minimally trained to operate and use. Heamac developed the product “nLite-360TM”, which is an intelligent phototherapy device for neonatal jaundice conditions. The device is AI-powered and can detect the condition of the baby on its own. Along with that it also shifts the device to the right mode of treatment which includes the angle of the light being projected and the angle of projection based on the condition of the neonate. Our device uses modern technology of Artificial Intelligence and Data Analytics to treat any condition of neonatal jaundice. This device requires the input parameters to be entered into the device. Once the parameters are available, the device primarily understands the jaundice risk level which serves as deciding factor for the phototherapy treatment using noninvasive measurement. Based on the data collected the algorithm of the device analyzes the data, detects the risk level of the neonate placed in the devices, and displays the risk level of the neonate. This process also displays the mode of treatment required, then sets itself to the right mode of treatment. The other key function of our device is that it does timely monitoring of the neonate placed in the device and based on the results it shifts the treatment accordingly. This will reduce the number of casualties. It is because jaundice is a dynamic condition and can vary instantaneously, thus it requires timely monitoring and variable intensity of phototherapy light and angle of projections, depending on the condition of the baby. The device has a multi-planar projection with a dynamic design, which maneuvers depending on the risk level of the neonate. This is not available in any of the presently used devices. Our technology of feedback system helps in understanding the right dosage and mode of treatment delivery which will have a scope to treat a baby with any dynamic condition of jaundice. Also adds the confidence to treat any robust conditions from rural care to private care. We believe that every new life deserves equal care.

Customers/Users: Heamac envisions saving the lives of 1 million newborns and soon being a part of India, rather the world where no baby ever dies of a completely preventable cause. The company is looking at establishing strong sales and distribution partners to penetrate 70 per cent of the market in India. We have a wide range of customers ranging from multispecialty hospitals, clinicians, physicians, maternal care units, delivery homes, gynaecologists, primary healthcare units, rural health centres, government hospitals, to homes. Annually 22000000 children are born and among them, 15000000 are affected by jaundice and we are addressing the burden of severe jaundice that is 45% of jaundice cases which is about 7000000 newborns per annum and there is no dedicated device existing to cater for this need. In India alone, there are 120,000 Hospitals (private nursing homes and corporate Hospitals ) and 1500 public health centres that cater to 25 million babies that are born every year. We calculate the impact scale as the total number of lives saved for each nLight360. This is the case with Indian markets. Once we have our product in India, we will move to other Asian and African countries. We are also looking for the expansion in the US with the support of our US partners and have received LoIs from users in UAE by taking part in the Arab Healthcare Summit 2020. We would then look for other European markets.

Revenue Model: Being a startup, we have a diversified revenue model. We follow the Direct Sales and Subscription Model approaches. In direct sales, we sell the product directly to the hospitals, which are our clinical partners. They will be charged on a one-time basis with free service and maintenance for a span of one year. Later, maintenance charges apply. In the subscription model, we’ll give our product to institutes and organizations on a subscription basis, charging them for a certain time and later providing renewal options. Direct sales will be feasible to multispecialty hospitals and the subscription model for the government and rural settings. We also have home monitoring devices that can be directly sold to the homecare settings, under the prescription of a physician, making another way of generating revenue for our product. We are tapping the unmet and unaddressed markets of primary and rural health care centers and aiming at multi-specialty hospitals. By collaborating with the government, we'll launch our product in government hospitals and delivery homes. Additionally, making use of the social media platforms and our network for early traction, attending and participating in conferences of UNICEF and WHO are broadening the market by enlightening crowds about our product.

Current traction: Our founders have done the Biodesign Fellowship where they have undergone clinical immersion and have done the need identification and need validation of our product. We then made a proof of concept of our idea with the CfHE incubation fund and have developed a working Prototype of our idea with the BIG Birac Grant. We are currently working on the Minimum Viable Product of our idea to meet the regulatory requirements and are parallel working on the project documentation to get NOC from CDSCO. We are planning to complete the Minimum Viable Product and the Pre-compliance testing of the device by the end of this year.

---

Promoters' Information

---

Products/Services